Skip to main content
. 2021 Nov 4;11:773078. doi: 10.3389/fonc.2021.773078

Table 1.

Clinical and pathological characteristics of the study population (n=1806 breast lesions).

Variable BC (n = 1806) Variable BC (n = 1806)
Age at diagnosis (years) 62 ± 13 [26–95] pN
BMI 26.7 ± 25.5 [14.2-46.1] 0 1204 (70.2%)
Hormonal Status 1 360 (21%)
Fertile 439 (24.3%) 2 88 (5.1%)
Pregnancy 2 (0.1%) 3 63 (3.7%)
Menopause 1347 (74.6%) Biological portrait
Replacement therapy 18 (1%) ER+/HER2- 1368 (80.9%)
Type of surgery ER+/HER2+ 144 (8.5%)
Conservative surgery 1345 (74.5%) ER-/HER2+ 69 (4.1%)
Mastectomy 461 (25.5%) ER-/HER2- 110 (6.5%)
Axillary dissection PG
No 1180 (65.3%) Negative 384 (21.3%)
Yes 626 (34.7%) Positive 1422 (78.7%)
LNS biopsy Ki67
No 316 (17.5%) ≤ 14% 1177 (65.2%)
Yes 1490 (82.5%) > 14% 629 (34.8%)
Type of breast cancer Radiotherapy
Microinvasive 27 (1.5%) No 504 (28.1%)
Invasive 1779 (98.5%) Yes 1288 (71.9%)
Histological type Chemotherapy
Ductal 1409 (78%) No 1218 (68.2%)
Lobular 278 (15.4%) Yes 567 (31.8%)
Others 119 (6.6%) Biological therapy
Grading No 1487 (89.6%)
I 190 (10.6%) Yes 173 (10.4%)
II 1133 (63.2%) Hormonal therapy
III 469 (26.2%) No 307 (17.2%)
Lymphovascular invasion Yes 1476 (82.8%)
No 1053 (58.6%) Exitus
Yes 744 (41.4%) No 1779 (98.0%)
Tumor dimension (mm) 15 ± 9 [0-100] Yes 37 (2.0%)
pT DM
X 7 (0.4%) No 1700 (94.1%)
1 1468 (81.3%) Yes 106 (5.9%)
2 305 (16.9%) Time to DM (months) 25 ± 25 [0-60]
3 12 (0.6%) LRR
4 14 (0.8%) No 1715 (92.6%)
Yes 91 (7.4%)
Time to LRR (months) 25 ± 25 [0-60]

BC, breast cancer; BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PG, progesterone receptor; DM, distant metastasis; LRR, locoregional recurrence.

Data are expressed as mean ± standard deviation or total numbers; range and frequency distribution are shown within square and round parentheses, respectively.